Vimarsana
Biggest News Aggregation in the World

Page 11 - Jon Patton News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jon Patton. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jon Patton Today - Breaking & Trending Today

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium - Vimarsana News

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium

Published: December 8, 2022

Thirteen of fourteen evaluable patients achieved disease control, with twelve showing tumor shrinkage SAN DIEGO and CALGARY, AB, Dec. 8, 2022 /CNW/ -- Oncolytics Biotech® Inc.'s Chinese... | December 8, 2022

Source: marketscreener.com
Related Topics:
United StatesSan AntonioSouth KoreaMatt CoffeyJon PattonHenryb GonzTimothy MccarthyLars BirgersonAdlai NortyeOncolytics Biotech IncCompany ContactOncolytics BiotechSecurities ExchangeConvention CenterSan Antonio Breast Cancer SymposiumAdlai Nortye PresidentChief MedicalNorth AmericanOncolytic North AmericanChief Executive OfficerBiotech IncOpen Label Phasei StudyOncolytic Virus Plus PaclitaxelChinese PatientsHormone Receptor Positive
Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer - Vimarsana News

Oncolytics Biotech® Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Published: December 1, 2022

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track...

Source: prnewswire.com
Related Topics:
Matt CoffeyJon PattonTimothy MccarthyOncolytics Biotech IncSociety For Immunotherapy Of CancerCompany ContactOncolytics BiotechSecurities ExchangeDrug AdministrationAnnual MeetingFast TrackChief Executive OfficerAccelerated ApprovalPriority ReviewEnglj MedSecurities Exchange ActOncolytics Biotech Inc
Oncolytics Biotech Inc.: Oncolytics Biotech Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer - Vimarsana News

Oncolytics Biotech Inc.: Oncolytics Biotech Receives FDA Fast Track Designation for the Treatment of Advanced/Metastatic Pancreatic Cancer

Published: December 1, 2022

FDA Fast Track designation granted after presentation at the SITC 37th Annual Meeting demonstrating 69% objective response rate SAN DIEGO, and CALGARY, AB, Dec. 1, 2022 /PRNewswire/ --

Source: finanznachrichten.de
Related Topics:
Matt CoffeyKostenloser WertpapierhandelJon PattonTimothy MccarthyOncolytics Biotech IncSociety For Immunotherapy Of CancerCompany ContactSecurities ExchangeDrug AdministrationAnnual MeetingFast TrackChief Executive OfficerOncolytics BiotechAccelerated ApprovalPriority ReviewEnglj MedSecurities Exchange Act
Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium - Vimarsana News

Oncolytics Biotech® Announces Presentations at the Upcoming San Antonio Breast Cancer Symposium

Published: November 21, 2022

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of two abstracts for poster presentations at the upcoming...

Source: prnewswire.com
Related Topics:
San AntonioUnited StatesSouth KoreaJon PattonHenryb GonzTimothy MccarthyAdlai NortyeOncolytics Biotech IncCompany ContactCancer ResearchOncolytics BiotechSecurities ExchangeConvention CenterProgram NumberSan Antonio Breast Cancer SymposiumInnovative Cancer ResearchOpen Label Phasei StudyOncolytic Virus Plus PaclitaxelChinese PatientsHormone Receptor PositiveNegative AdvancedMetastatic Breast CancerPoster SessionOncolytic North AmericanPelareorep Primes
Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort - Vimarsana News

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study's Pancreatic Cancer Cohort

Published: November 10, 2022

/PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced updated results from the phase 1/2 GOBLET study's first-line...

Source: prnewswire.com
Related Topics:
United StatesThomasc HeinemanD Asklepios TumorzentrumDirk ArnoldTimothy MccarthyMatt CoffeyJon PattonAndrea BullockThomas SeufferleinOncolytics Biotech IncSociety For Immunotherapy Of CancerExhibition CenterCompany ContactBeth Israel Deaconess Medical CenterGerman Cancer SocietyBoston ConventionPhd Ulm UniversityOncolytics BiotechSecurities ExchangeAnnual MeetingChief Medical OfficerChief Executive OfficerAsklepios Tumorzentrum HamburgUlm UniversityEnglj Med